Molecular Psychiatry
August 23, 2025
Adam J. Drewko, Ron L. P. Habets, Tibor M Brunt
4 citations
Serotonergic psychedelics, including the recreationally used psilocybin and LSD, have become promising therapeutic agents for the treatment of treatment-resistant depression. While it is generally agreed that they exhibit their antidepressant effects by inducing rapid and sustained neuroplasticity, the molecular mechanisms responsible are widely debated. In particular, the role of the serotonin...
Therapeutic Drug Monitoring
April 1, 2020
Funda Inan, Tibor M Brunt, Ramon R Contrucci et al.
9 citations
The novel phenethylamines 4-fluoroamphetamine (4-FA) and 2,5-dimethoxy-4-bromophenethylamine (2C-B) fall in the top 10 most used new psychoactive substances (NPSs) among high-risk substance users. Various phenethylamines and NPS are also highly used in populations with mental disorders, depression, or attention deficit hyperactivity disorder (ADHD). Moreover, NPS use is highly prevalent among...
Journal of Forensic Sciences
November 1, 2019
Antoinette S Spoelder, Jan K G Louwerens, Stefanie D Krens et al.
12 citations
4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a designer drug. In Europe, 2C-B is easily obtained and used for recreational purposes. It is known for its stimulating effects similar to those of 3,4-methylenedioxymethamphetamine, although in higher doses it has more hallucinogenic effects. Here, we report a case of 2C-B ingestion, confirmed by liquid chromatography-tandem mass spectrometry, in...
Addiction (Abingdon, England)
April 1, 2017
Daan van der Gouwe, Tibor M Brunt, Margriet Van Laar et al.
72 citations
On-line drug markets flourish and consumers have high expectations of on-line quality and drug value. The aim of this study was to (i) describe on-line drug purchases and (ii) compare on-line with off-line purchased drugs regarding purity, adulteration and price. Comparison of laboratory analyses of 32 663 drug consumer samples (stimulants and hallucinogens) purchased between January 2013 and...
Clinical Toxicology
May 31, 2016
Tibor M Brunt, Ruud P. W. Litjens
We concur with the observation of the authors that ibogaine does not seem to have a clear therapeutic dose margin, nor does iboga extracts or the root bark of iboga. However, what they consider to ...
Clinical toxicology (Philadelphia, Pa.)
2016
Ruud P. W. Litjens, Tibor M Brunt
74 citations
Ibogaine is a psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe Iboga. It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause for concern. To review ibogaine's pharmacokinetics and pharmacodynamics, mechanisms of action and reported toxicity. A search of the literature available on PubMed was done,...
Drug and Alcohol Dependence
December 1, 2015
Johanna J Nugteren-Van Lonkhuyzen, Antoinette J H P van Riel, Tibor M Brunt et al.
48 citations
Recently, the number of new psychoactive substances (NPS) appearing on the illicit drug market has shown a marked increase. Although many users perceive the risk of using NPS as medium or low, these substances can pose a serious health risk and several NPS have been implicated in drug-related deaths. In Europe, frequently detected NPS are 4-bromo-2,5-dimethoxyphenethylamine (2C-B),...
Drug and Alcohol Dependence
February 1, 2015
Laura Hondebrink, Johanna J Nugteren-Van Lonkhuyzen, Daan van der Gouwe et al.
119 citations
In recent years, the number of new psychoactive substances (NPS) appearing on the illicit drug market strongly increased. However, little is known about their toxic effects and risks. Therefore, we determined the most frequently occurring NPS in The Netherlands and combined this with data regarding drug-related intoxications. Data from the Drugs Information and Monitoring System (DIMS) and the...
The International journal on drug policy
March 2012
Tibor M Brunt, Raymond J M Niesink, Wim Van den Brink
A recent decline in MDMA-like substances in ecstasy tablets has been reported by a number of countries in the European Union. This study describes the instability of the ecstasy market in The Netherlands during 2008 and 2009, and investigates whether this had any impact on drug testing or patterns of drug use. The health concerns of drug users handing in drug samples at drug testing facilities...
Journal of Psychopharmacology
September 8, 2010
Tibor M Brunt, Anneke Poortman, Raymond J.m. Niesink et al.
217 citations
Recently, several reports have indicated instability of the ecstasy market in the Netherlands and other EU countries. In the current study, we demonstrate this instability in the Netherlands, showing a decrease of ecstasy tablets containing 3,4-methylenedioxymetamphetamine (MDMA) by more than 50% in 2009. In addition, we describe a partial replacement of MDMA in tablets sold as ecstasy by a...
Journal of psychopharmacology (Oxford, England)
September 2010
M G Bossong, T M Brunt, J P Van Dijk et al.
A new ecstasy-like substance, meta-chlorophenylpiperazine (mCPP), has been detected in street drugs in the Netherlands. Theoretically, mCPP possesses the potential to become a non-neurotoxic alternative for methylenedioxymethamphetamine (MDMA), the regular psychoactive substance of ecstasy. Since its introduction on the Dutch market of synthetic drugs, the percentage of mCPP-containing tablets...